Longitudinal microRNA profiles in breast cancer tissue and plasma: Associations with hormone receptors, response, and survival

Figure 7 miR-155 expression. A: MiR-155 levels in adjacent non-tumor tissue, primary tumors, and post-neoadjuvant chemotherapy tumor samples; B: Changes in miR-155 levels in hormone receptor-positive and hormone receptor-negative breast tumors; C: Plasma miR-155 levels at baseline, after neoadjuvant chemotherapy, and at the end of treatment; D: Overall survival according to miR-155 expression in primary breast tumors. Patients were stratified into high and low expression groups. Survival probabilities were calculated using the Kaplan-Meier method, with cumulative hazard functions estimated via the Nelson-Meier estimator. NACT: Neoadjuvant chemotherapy; EOT: End of treatment; HR: Hormone receptor; OS: Overall survival; NR: Not reached; NA: Not applicable; HR: Hazard ratios; CI: Confidence interval.